现货型诱导多能干细胞来源自然杀伤细胞疗法治疗复发或难治性B细胞淋巴瘤:一项多中心、开放标签、1期研究
这项在美国8个研究中心开展的多中心、开放标签、1期研究评估了FT516(一种表达高亲和力、不可切割CD16的诱导多能干细胞来源自然杀伤细胞疗法)联合单克隆抗体和IL-2治疗复发或难治性B细胞淋巴瘤的安全性。2019年10月11日至2022年11月28日共入组56例患者,55例接受FT516;最大细胞剂量(9×10^8个细胞/剂,每28天周期3剂)可耐受并确定为2期推荐剂量,未报告剂量限制性毒性;客观缓解见于55例中的32例(58%)。
要点
- FT516最大剂量9×10^8个细胞/剂(每28天周期3剂)可耐受,确定为2期推荐剂量。
- 未报告剂量限制性毒性;细胞因子释放综合征见于1例(2%)且为1级,未观察到神经毒性。
- 3级及以上最常见不良事件为中性粒细胞减少46例(84%)、血小板减少20例(36%)、贫血15例(27%)。
核心结论
- 研究结果表明,使用诱导多能干细胞来源、基因修饰的自然杀伤细胞联合单克隆抗体和IL-2的细胞疗法在B细胞恶性肿瘤中安全且有活性,可能解决现有免疫细胞疗法在制造时间、异质性、可及性和成本方面的局限。
研究设计与样本
- 多中心、开放标签、1期研究,在美国8个研究中心开展。
- 入组年龄18岁及以上、预期表达CD20的B细胞淋巴瘤、至少接受过一种包括抗CD20抗体的既往全身治疗后复发或难治、有可测量病灶且无预期可改善生存的治疗选择的患者。
- 患者接受氟达拉滨(30 mg/m2,第-5至-3天,共3天)和环磷酰胺(500 mg/m2,第-5至-3天,共3天)或苯达莫司汀(90 mg/m2,第-4和-3天,共2天),联合利妥昔单抗375 mg/m2(第-4天),或在剂量扩展期间滤泡性淋巴瘤患者以奥妥珠单抗1000 mg替代利妥昔单抗。
- 主要终点为安全性,包括剂量限制性毒性和最大耐受剂量;安全性在所有接受至少一剂FT516的患者中分析。
主要发现
- 2019年10月11日至2022年11月28日入组56例患者,其中55例接受FT516;32例(58%)为男性,23例(42%)为女性,43例(78%)为白人。
- 最大FT516细胞剂量(9×10^8个细胞/剂,每28天周期3剂)可耐受,确定为2期推荐剂量;未报告剂量限制性毒性。
- 细胞因子释放综合征见于1例(2%)患者,为1级;未观察到神经毒性。
- 3级及以上最常见不良事件为中性粒细胞减少(46例[84%])、血小板减少(20例[36%])和贫血(15例[27%]);无治疗相关死亡。
- 55例患者中32例(58%)观察到客观缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Natural killer-cell therapies are limited by donor cell sourcing and dose-to-dose variability. FT516 is an induced pluripotent stem cell (iPSC)-derived natural killer-cell therapy expressing high-affinity, non-cleavable CD16 to optimise antibody-dependent cellular cytotoxicity in combination with therapeutic monoclonal antibody. We aimed to assess the safety of FT516 in patients with relapsed or refractory B-cell lymphoma. METHODS: This multicentre, open-label, phase 1 study was conducted at eight research centres in the USA. Eligible patients were aged 18 years or older, had B-cell lymphoma expected to express CD20, with relapsed or refractory disease following at least one previous systemic therapy including anti-CD20 antibody, had measurable disease, and had no treatment options expected to improve survival. Participants received fludarabine (30 mg/m2 for 3 days on days -5 to -3) and cyclophosphamide (500 mg/m2 for 3 days on days -5 to -3) or bendamustine (90 mg/m2 for 2 days on days -4 and -3) combined with rituximab at 375 mg/m2 on day -4 or obinutuzumab 1000 mg replaced rituximab in patients with follicular lymphoma during dose expansion. FT516 was administered intravenously at escalating doses, ranging from 3 × 107 to 9 × 108 cells per dose on days 1, 8, and 15, with IL-2 (6 million units) administered subcutaneously 2-4 h after each FT516 dose. The primary endpoint was safety, including dose-limiting toxicity and maximum tolerated dose. Safety was analysed in all patients who received at least one dose of FT516. Patients with acute myeloid leukaemia were also enrolled and will be reported elsewhere. This study was registered with ClinicalTrials.gov, NCT04023071, and is completed. FINDINGS: From Oct 11, 2019, to Nov 28, 2022, 56 patients were enrolled, 55 of whom received FT516. 32 (58%) patients were male, 23 (42%) were female, and 43 (78%) were White. The maximum FT516 cell dose (9 × 108 cells per dose for three doses per 28-day cycle) was tolerated and identified as the recommended phase 2 dose. No dose-limiting toxicities were reported. Cytokine release syndrome was reported in one (2%) patient and was grade 1; neurotoxicity was not observed. Most common adverse events grade 3 or worse were neutropenia (in 46 [84%] patients), thrombocytopenia (20 [36%]), and anaemia (15 [27%]). There were no treatment-related deaths. Objective response was observed in 32 (58%) of 55 patients. INTERPRETATION: Our findings suggest that cell therapy using iPSC-derived, gene-modified natural killer cells in combination with monoclonal antibody and IL-2 is safe and active in B-cell malignancies and might address limitations of currently available immune-cell therapies, including manufacturing time, heterogeneity, access, and cost. FUNDING: Fate Therapeutics.
引用
- Strati P, Castro J, Goodman A, et al. Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study. Lancet Haematol. 2025. PMID: 40610174. doi:10.1016/S2352-3026(25)00142-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。